{"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.537","pValueComment":"One-sided p-value.","statisticalComment":"Exact binomial test compares versus a proportion of 0.25.","statisticalMethod":"Exact binomial test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.2","upperLimit":"34.3","value":"25.0"}]}],"title":"Overall response rate (ORR)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.3","upperLimit":"14.1","value":"7.4"}]}],"title":"Complete response rate (CR rate)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.9","upperLimit":"26.1","value":"17.6"}]}],"title":"Partial response rate (PR rate)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"description":"Overall response by Computed Tomography (CT) as defined by achieving complete response and/or partial response assessed by an Independent Review Committee (IRC) utilizing the modified Lugano Classification Revised Staging System for malignant lymphoma (Cheson, 2014).","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).","id":"OG000","title":"Cohort A"}],"paramType":"NUMBER","populationDescription":"The full analysis set (FAS) followed the intent to treat (ITT) principle and consisted of all subjects who received at least one dose of AFM13.","reportingStatus":"POSTED","timeFrame":"Tumor assessment performed every 8 weeks for first 3 assessments, then every 12 weeks until documented disease progression (up to 46 months).","title":"Complete Response Rate, Partial Response Rate and Overall Response Rate Assessed by Independent Review Committee Based on CT","type":"SECONDARY","unitOfMeasure":"percentage"}